As of Friday close, Elanco Animal Health Incorporated’s (NYSE:ELAN) stock was up $0.58, moving up 2.67 percent to $22.27. The average number of shares traded per day over the past five days has been 7,017,500 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.52 fall in that time frame. In the last twenty days, the average volume was 5,006,220, while in the previous 50 days, it was 4,271,176.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, ELAN stock retreated -15.19%. Shares of the company fell to $20.51 on 05/12/22, the lowest level in the past month. A 52-week high of $37.49 was reached on 03/03/22 after having rallying from a 52-week low of $20.51. Since the beginning of this year, ELAN’s stock price has dropped by -21.53% or -$6.11, and marked a new high 8 times. However, the stock has declined by -40.60% since its 52-week high.
Elanco Animal Health Incorporated (ELAN) last reported insider trading activity 3 days ago on May 11. BILBREY JOHN P, the Director of the company, purchased of 10,000 shares for $22.03 on May 11. It resulted in a $220,284 investment by the insider. HOOVER R DAVID added 5,000 shares at an average price of $29.00 on Mar 02. The insider now owns 115,000 shares following the transaction. On Mar 01, Director Anand Kapila K bought 1,000 shares at $28.48 apiece. The transaction was valued at $28,479.
The stock’s beta is 0.74. Besides these, the trailing price-to-sales (P/S) ratio of 2.25, the price-to-book (PB) ratio of 1.44, and the price-to-cash flow ratio of 30.02 may also be considered.
In the three months ended September 29, Elanco Animal Health Incorporated’s quick ratio stood at 1.20, while its current ratio was 2.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.80, and the total debt-to-equity ratio was 0.84. On the profitability front, the trailing twelve-month gross margin is 55.20% percent. In the year ended September 29, operating margins totaled -6.80%. Based on annual data, ELAN earned $2.63 billion in gross profit and brought in $4.76 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -1.70%. Return on equity (ROE) for the past 12 months was -6.00%.
In Elanco Animal Health Incorporated’s quarter-end financial report for September 29, it reported total debt of $6.07 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ELAN’s revenue fell -1.39% to $1.11 billion during the quarter, while net income inched up to $1.23 billion. While analysts expected Elanco Animal Health Incorporated to report $0.16 quarterly earnings, the actual figure was $0.19 per share, beating the consensus estimate by 18.80%. During the quarter, the company generated $308.0 million in EBITDA. The liabilities of Elanco Animal Health Incorporated were 8.64 billion at the end of its most recent quarter ended September 29, and its total debt was $6.36 billion. The value of shareholders’ equity is $474.1 million.
This quick technical analysis looks at Elanco Animal Health Incorporated’s (ELAN) price momentum. With a historical volatility rate of 57.23%, the RSI 9-day stood at 34.34% on 13 May.
With respect to its five-day moving average, the current Elanco Animal Health Incorporated price is down by -6.39% percent or -$1.52. At present, ELAN shares trade -15.16% below its 20-day simple moving average and -21.03% percent below its 100-day simple moving average. However, the stock is currently trading approximately -21.50% below its SMA50 and -39.17% below its SMA200.
Stochastic coefficient K was 18.25% and Stochastic coefficient D was 10.38%, while ATR was 1.01. Given the Stochastic reading of 32.18% for the 14-day period, the RSI (14) reading has been calculated as 34.04%. As of today, the MACD Oscillator reading stands at -1.38, while the 14-day reading stands at -2.26.
Morgan Stanley launched its rating on Elanco Animal Health Incorporated (NYSE: ELAN) to an Overweight in a note to investors on November 18, 2021. Elanco Animal Health Incorporated (ELAN) has been rated Overweight by analysts. According to 0 brokerage firms, ELAN is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Elanco Animal Health Incorporated stock as buy, with 6 recommending it as overweight.
With a median target price of $37.00, the current consensus forecast for the stock is $30.00 – $40.00. Based on these forecasts, analysts predict Elanco Animal Health Incorporated (ELAN) will achieve an average price target of $35.29.